NewsRoom Articles - BioMedWire (BMW)

ThursdayJun 18, 2026 10:30 am

Earth Science Tech Inc. (ETST) Signals Strong Confidence with Aggressive Q1 Share Buybacks

Aggressive repurchase of its own stock by Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reflects management’s growing internal confidence in the company’s future trajectory. Over 3 million shares of common stock have been repurchased in current fiscal quarter, a significant acceleration in buybacks. Reduction in share dilution can consolidate existing equity and potentially boost earnings per share (“EPS”). Earth Science Tech (OTC: ETST) is capturing the attention of the micro-cap market following a significant acceleration of its share repurchase program. Recent market data indicates that the company is aggressively buying back its own…

ThursdayJun 18, 2026 10:00 am

CMS Issues Final Rules on Medicaid Eligibility Work Requirements

Last year, Congress passed changes to Medicaid eligibility requirements and CMS was given a deadline to issue final rules on those work requirements. The federal agency has since published those final rules and enrollees on the Medicaid program need to acquaint themselves with these requirements to ensure they comply in order to retain their eligibility. We discuss some of those requirements. The rules, published on June 1, aren’t going to affect every person enrolled on Medicaid. Instead, they will affect individuals whose coverage is in the category of Medicaid expansion. This program is offered in some, but not all, states around the country. Under Medicaid expansion, adults who earn a low income…

ThursdayJun 18, 2026 9:00 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Launches Lead Commercial Software Intox AI(TM) for Multiple Forms of Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The platform is designed to detect cocaine, cannabis, alcohol, narcotics, psychedelics, and human fatigue using voice analysis and artificial intelligence. MindBio is preparing to deploy the software through Edge AI kiosk systems targeted at safety-critical industries. The company is pursuing commercialization opportunities in mining, aviation, construction, transportation, and law enforcement markets. MindBio’s technology offers a non-invasive and affordable alternative to traditional drug and alcohol testing methods. The launch represents a key step in the company’s transition from research and clinical development toward commercial implementation. MindBio Therapeutics…

TuesdayJun 16, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Working to Help Employers Tackle Cardiovascular Risk, Healthcare Costs

Cardiovascular disease remains one of the most expensive health conditions in the United States. Cardio Diagnostics announced plans to participate in four national benefits conferences during June. The company has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses. As cardiovascular disease continues to drive a significant share of healthcare spending, organizations responsible for…

TuesdayJun 16, 2026 10:00 am

How Authorities are Protecting Public Health During the FIFA World Cup

The FIFA World Cup started on June 11 and will end on July 19. 48 national teams are taking part, and this is an extra 16 teams when compared to the number of national teams that participated in the last edition that took place in Qatar in 2022. 100 matches are scheduled to be played across the U.S., Mexico and Canada. An international sporting event of this magnitude presents a major challenge to public health planners, and authorities have been working fervently to put in place measures geared at keeping infectious disease risks at bay during the tournament. We discuss…

FridayJun 12, 2026 10:00 am

Study Links TBI to Higher Mortality Risk Due to Brain Cancer

A study conducted by a team at Mass General Brigham has found that people with a history of traumatic brain injury had a higher chance of dying as a result of brain cancer. The findings create an urgency to rethink how TBI cases are handled not just in the immediate aftermath but also over the long term. The study, whose findings were published in the journal Neuroepidemiology, analyzed a national database of more than 20,000 patients who had been treated for traumatic brain injury over a period of 37 years (1987–2024). The investigators were especially interested in finding out how a history of TBI impacted mortality risk in brain cancer,…

FridayJun 12, 2026 9:45 am

Earth Science Tech Inc. (ETST) Reports Transformational Fiscal Year as Share Repurchases and Healthcare Expansion Shape Growth Strategy

Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reported a series of operational milestones in its fiscal year ended March 31, 2026, highlighted by expansion across its healthcare platform and continued cash-flow generation. Earth Science Tech repurchased and retired more than 6.9 million shares of common stock since fiscal Q1 2026, underscoring management’s focus on reducing share dilution in support of shareholder value. Key operating businesses, including DOConsultation, Villas Health and MOC Teledoc, are now cash-flow positive. Peaks Curative surpassed $2 million in revenue during the first week of fiscal Q4 2026, reflecting…

ThursdayJun 11, 2026 10:00 am

FIU Researchers Discover New Way of Extending Immune Cell Lifespan and Effectiveness

CAR-T therapy has been transformational in treating many blood cancers, such as leukemia and lymphoma. However, this treatment approach hasn’t worked for solid tumors, and it also reaches a point and becomes ineffective in blood cancers. A new study just found a way to boost the lifespan and efficacy window of these important immune cells that help fight cancer. The study, whose findings appeared in the journal Frontiers in Immunology, was conducted by a team at Florida International University (FIU). The researchers spent about five years studying why cancer-fighting immune cells lose their effectiveness and don’t survive for long. They were particularly interested in establishing how tumor cells develop a protective mechanism against the immune cells…

ThursdayJun 11, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. Through its focus on ADCs and TCEs, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market. Via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (“RICs”) and antibody-oligonucleotide conjugates (“AOCs”). VERAXA Biotech has successfully concluded a business combination…

WednesdayJun 10, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Onco-Innovations is developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response therapy market that is distinct from established PARP inhibitor therapies. Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has…